Table 1.
Effect estimates for recurrent cancer according to biological target
| Previous cancer | Effect size | Analysis | Sub-group | Studies, n | Biologic group | Conventional therapy group | Fixed effects | Random effects | Heterogeneity | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sample size/person-years, n | Cancer events, n | Sample size/person-years, n | Cancer events, n | Effect size [95% CI] | p value | Effect size [95% CI] | p value | I2 [95% CI], % | Egger’s test | |||||
| Tumor Necrosis Factor-α inhibitor | ||||||||||||||
| Mixed | RR | Main | 11 | 1889 | 162 | 8752 | 444 | 1.05 [0.88; 1.25] | 0.6 | 1.09 [0.78; 1.52] | 0.56 | 51.6% [3.9%; 75.7%] | 0.79 | |
| Mixed | RR | Sensitivity | Influence analysis | 7 | 775 | 43 | 5070 | 144 | 1.25 [0.87; 1.79] | 0.22 | 1.33 [0.90; 1.96] | 0.12 | 0.0% [0.0%; 70.8%] | – |
| Mixed | RR | Sensitivity | Remove no therapy | 8 | 1565 | 124 | 8121 | 376 | 1.18 [0.97; 1.44] | 0.10 | 1.20 [0.85; 1.69] | 0.25 | 41.9% [0.0%; 74.3%] | – |
| Mixed | RR | Subgroup | Disease | – | – | – | – | Test for subgroup differences: | 0.10 | – | 0.76 | – | – | |
| Mixed | RR | IBD | 5 | 431 | 50 | 798 | 80 | 0.82 [0.60; 1.14] | 0.23 | 1.00 [0.43; 2.33] | 0.99 | 42% [0%; 79%] | – | |
| Mixed | RR | RA | 4 | 988 | 94 | 3554 | 257 | 1.14 [0.91; 1.43] | 0.27 | 1.12 [0.48; 2.60] | 0.68 | 73% [23%; 90%] | – | |
| Mixed | RR | Subgroup | Follow-up time | – | – | – | – | Test for subgroup differences: | 0.15 | – | 0.04 | – | – | |
| Mixed | RR | < 5 years | 3 | 154 | 18 | 400 | 23 | 1.52 [0.81; 2.84] | 0.19 | 1.52 [0.90; 2.57] | 0.07 | 0% [0%; 90%] | – | |
| Mixed | RR | > 5 years | 7 | 1515 | 123 | 7176 | 351 | 0.94 [0.77; 1.14] | 0.52 | 0.94 [0.58; 1.52] | 0.75 | 60% [7%; 82%] | – | |
| Mixed | IRR | Main | 9 | 10,347 | 150 | 34,236 | 430 | 0.83 [0.69; 1.01] | 0.06 | 0.83 [0.58; 1.20] | 0.28 | 42.3% [0.0%; 73.4%] | – | |
| Mixed | IRR | Sensitivity | Remove no therapy | 6 | 7644 | 112 | 29,628 | 362 | 0.89 [0.72; 1.11] | 0.32 | 0.88 [0.59; 1.31] | 0.44 | 38.4% [0.0%; 75.5%] | – |
| Mixed | HR | Main | Adjusted estimates | 3 | 1121 | 75 | 7668 | 323 | – | – | 0.97 [0.39; 2.42] | 0.89 | 38.6% [0.0%; 80.8%] | – |
| Mixed | HR | Sensitivity | > 500 patients | 3 | 1121 | 75 | 7668 | 323 | – | – | 0.97 0,39; 2.42] | 0.89 | 38.6% [0.0%; 80.8%] | – |
| Anti-α4β7-integrin | ||||||||||||||
| Mixed | RR | Main | 3 | 167 | 14 | 631 | 68 | 0.51 [0.30; 0.87] | 0.01 | 0.70 [0.07; 7.61] | 0.59 | 60.5% [0.0%; 88.7%] | – | |
| Mixed | IRR | Main | 3 | 1396 | 14 | 4608 | 68 | 0.45 [0.26; 0.80] | 0.006 | 0.63 [0.05; 7.83] | 0.50 | 59.7% [0.0%; 88.5%] | – | |
p values < 0.05 marked bold
NMSC, Non-Melanoma Skin Cancer; RR, Risk Ratio; HR, Hazard Ratio; IRR, Incidence Rate Ratio; IL, Interleukin